Brief: Regeneron Says FDA Approves Pasatru (Garetosmab-Grts) For Adults With Fibrodysplasia Ossificans Progressiva
19/08/2026 20:19
BRIEF-Regeneron Says FDA Approves Pasatru (Garetosmab-Grts) For Adults With Fibrodysplasia Ossificans Progressiva Aug 20 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
REGENERON PHARMACEUTICALS, - FDA APPROVES PASATRU (GARETOSMAB-GRTS) FOR ADULTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
REGENERON PHARMACEUTICALS, - PASATRU UNDER REVIEW BY EUROPEAN MEDICINES AGENCY; GLOBAL SUBMISSIONS PLANNED
Source text: ID:nGNX8Zxk5Z
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement